# A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression

> **NCT01706575** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 76 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Pegylated Interferon (Peginterferon) Alfa-2a
- **DRUG:** Nucleos(t)ide Analogues (NA)

## Key facts

- **NCT ID:** NCT01706575
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-09
- **Final completion:** 2014-11
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2017-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01706575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01706575, "A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01706575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*